Kevin Felpel

Kevin Felpel

Auto-generated profile, based on publicly available information

Kevin Felpel

Division of Cardiovascular Medicine, University of Utah, Salt Lake City, UT, U.S.A

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in The American Journal of Medicine
Verified
Journal Article
Closed access
Ahmed AbuzaidAhmed Abuzaid
Ahmed Abuzaid
CFCarly Fabrizio
Carly Fabrizio
KFKevin Felpel
Kevin Felpel
HAHaitham S. Al Ashry
Haitham S. Al Ashry
PRPragya Ranjan
Pragya Ranjan
IEIslam Elgendy
Islam Elgendy

1 September 2021 in Nutrition
Verified
Journal Article
Closed access
KFKevin Felpel
Kevin Felpel
LPLidia Palmese
Lidia Palmese
LULuis Urrutia
Luis Urrutia
ZZZugui Zhang
Zugui Zhang
MSMary Shapero
Mary Shapero
MVMichael T. Vest
Michael T. Vest

1 August 2018 in Structural Heart
Verified
Journal Article
Open access
Ahmed AbuzaidAhmed Abuzaid
Ahmed Abuzaid
PRPragya Ranjan
Pragya Ranjan
CFCarly Fabrizio
Carly Fabrizio
KFKevin Felpel
Kevin Felpel
RCRaveen Chawla
Raveen Chawla
IEIslam Elgendy
Islam Elgendy
Background: The optimal anti-platelet regimen after transcatheter aortic valve replacement (TAVR) remains uncertain. The objective of this study was to compare the efficacy and safety of single anti-platelet therapy (SAPT) vs. dual anti-platelet therapy (DAPT) after transcatheter aortic valve replacement (TAVR). Methods: Electronic databases were searched for randomized and observational studies, which compared SAPT versus DAPT after TAVR. The primary outcomes were all-cause mortality, and major bleeding. Summary adjusted risk ratios (RR) were calculated using a Der-Simonian and Liard model. The risk of bias of the included studies was assessed by the Cochrane scale and New-castle Ottawa assessment tool. Results: A total of 10 studies with 2,412 patients were included. There was no difference in 30-days all-cause mortality (RR 1.19, 95% CI 0.79–1.81, p = 0.41, I2 = 0.0%) and at the longest available follow up (i.e. mean 6.4 months) (RR 1.03, 95% CI 0.69–1.57, p = 0.86, I2 = 0.0%). The risk of major bleeding was higher in the DAPT group (RR 2.14, 95% CI 1.37–3.31, p = 0.001). These findings were consistent on analyzing randomized versus observational studies (Pinteraction = 0.97, and 0.76 for all-cause mortality and major bleeding, respectively). There was no difference in the risk of life-threatening bleeding, major vascular complications, myocardial infarction, and stroke between both groups (all p-values > 0.05). Conclusion: DAPT post TAVR is associated with an increased risk of major bleeding with no benefit on mortality, stroke, or myocardial infarction. The evidence is driven mainly from observational studies, and therefore future high quality randomized trials are needed.

27 February 2019 in Journal of Nuclear Cardiology
Verified
Journal Article
Closed access
PDF file
SGShreyas Gowdar
Shreyas Gowdar
AAAlan W. Ahlberg
Alan W. Ahlberg
MRMridula Rai
Mridula Rai
WPWilliam H. Perucki
William H. Perucki
KFKevin D. Felpel
Kevin D. Felpel
WDW. Lane Duvall
W. Lane Duvall

27 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KFKevin Felpel
Kevin Felpel
JHJ. W. Awori Hayanga
J. W. Awori Hayanga
JMJ. Hunter Mehaffey
J. Hunter Mehaffey
CBChristopher Bianco
Christopher Bianco
MCMarco Anthony Caccamo
Marco Anthony Caccamo
GSGeorge Sokos
George Sokos
Purpose: Federal programs to mitigate hospital readmission of patients with heart failure (HF) monetarily encourage hospitals through the use of penalties. The limited performance of predictive models have created potential challenges of implementation and unintended consequences, with criticisms about its unintended consequences and the low performance of its predictive models. We study sought to refine existing predictive models of readmission using heart failure (HF) data from a large multi-payer national dataset. Methods: The Premier healthcare database, a nationally representative all-payor dataset, was utilized to examine over 300 variables from HF patients (2016-2023) including demographics, comorbidities, cardiac diagnoses, provider characteristics, medications, and lab values, defined using diagnosis-related group and ICD-10 codes. Outcomes from patients with primary and secondary HF diagnoses included 30-day all-cause readmissions and 30-day HF-related readmissions. Data were divided into training (60%), validation (20%), and testing (20%) sets. We evaluated logistic regression, random forest, neural networks, modified neural networks, support vector machines, naïve Bayesian decision trees, and XGBoost models, comparing them based on accuracy (AUC), precision, recall, and F-score. Results: Of 722,974 HF patients examined, 12.0% and 11.3% experienced all-cause and HF-related 30-day readmissions, respectively. Mean age was 71 years and 48% were female. A total of 68,649 patients readmitted with a primary HF diagnosis for homogeneity (2021-2023) was thoroughly analyzed using multiple contemporary Bayesian and non-Bayesian models. This subset was 47% female with a mean age of 72 years. The XGBoost model performed best, with an AUC of 0.63 for all-cause and 0.62 for HF-related readmissions. The key predictors of readmissions were age and chronic non-cardiac comorbidities instead of HF-specific factors. Conclusion: Contemporary statistical models applied to nationally representative contemporary real-world data struggle to identify modifiable interventions, suggesting that existing federal programs may penalize without actionable improvements in patient care.

1 June 2019 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
SSS Saucier
S Saucier
ASA Singhvi
A Singhvi
IVI Verma
I Verma
KFK Felpel
K Felpel
AGA Gabriel
A Gabriel
WDW L Duvall
W L Duvall
Background: Attenuation correction (AC) hardware and software has been shown to increase the specificity of SPECT MPI decreasing false positive results and improving the prognostic ability of results. These benefits should reduce subsequent unnecessary confirmatory coronary angiography. We sought to assess the implication of Gd-153 scanning line source AC on downstream invasive testing.